Roy J. Duhe

Affiliations: 
The University of Mississippi Medical Center, Jackson, MS, United States 
Area:
Pharmacology, Biochemistry, Molecular Biology
Google:
"Roy Duhe"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Zouein FA, Duhé RJ, Arany I, et al. (2014) Loss of STAT3 in mouse embryonic fibroblasts reveals its Janus-like actions on mitochondrial function and cell viability. Cytokine. 66: 7-16
Duhé RJ. (2013) Redox regulation of Janus kinase: The elephant in the room. Jak-Stat. 2: e26141
Kurdi M, Sivakumaran V, Duhé RJ, et al. (2012) Depletion of cellular glutathione modulates LIF-induced JAK1-STAT3 signaling in cardiac myocytes. The International Journal of Biochemistry & Cell Biology. 44: 2106-15
Smith JK, Patil CN, Patlolla S, et al. (2012) Identification of a redox-sensitive switch within the JAK2 catalytic domain. Free Radical Biology & Medicine. 52: 1101-10
Zouein FA, Duhé RJ, Booz GW. (2011) JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth. Growth Factors (Chur, Switzerland). 29: 245-52
Kundrapu K, Colenberg L, Duhé RJ. (2008) Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation. Cell Biochemistry and Biophysics. 52: 103-12
Mamoon NM, Smith JK, Chatti K, et al. (2007) Multiple cysteine residues are implicated in Janus kinase 2-mediated catalysis. Biochemistry. 46: 14810-8
Lee S, Duhé RJ. (2006) Kinase activity and subcellular distribution of a chimeric green fluorescent protein-tagged Janus kinase 2. Journal of Biomedical Science. 13: 773-86
Chatti K, Farrar WL, Duhé RJ. (2004) Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry. 43: 4272-83
Smith JK, Mamoon NM, Duhé RJ. (2004) Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncology Research. 14: 175-225
See more...